Skip to content

MDT to Evaluate the Survival Benefit of Patients With Advanced Gastric / Colorectal Cancer

A Prospective, Multicenter, Prospective, Non-intervention, Controlled Trial of MDT to Evaluate the Survival Benefit of Patients With Advanced Gastric / Colorectal Cancer in Realistic Medical Practice

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03400657
Enrollment
484
Registered
2018-01-17
Start date
2017-11-01
Completion date
2020-06-30
Last updated
2018-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multi-disciplinary Treatment

Brief summary

This is a prospective, multicenter, non-interventional, controlled clinical study. Evaluate MDT performance and benefit analysis in patients with advanced gastric or colorectal cancer after MDT discussion under real medical practice.

Interventions

PROCEDUREMulti-disciplinary Treatment

due to suggestion of Multi-disciplinary Treatment ,the patients would be suggested to chemotherapy or surgery.

Sponsors

Peking University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Histopathological diagnosis of recurrent / metastatic gastric or colorectal cancer. 2. Participate in formal MDT discussions at the Research Center. 3. MDT decision-making at least two subjects involved in treatment. 4. Patient informed consent and signed written consent.

Exclusion criteria

1. Early or locally advanced gastric cancer or colorectal cancer. 2. Accept informal MDT discussions. 3. MDT decisions recommend only a single subject for treatment of patients. 4. MDT decisions recommend only palliative patients.

Design outcomes

Primary

MeasureTime frameDescription
overall survivalFrom date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 monthsFrom date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Secondary

MeasureTime frameDescription
Differences in overall survival after performing MDT at center1 yearsDifferences in overall survival after performing MDT at center

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026